chlortalidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
625 77-36-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clortalidone
  • phthalamudine
  • chlorphthalidolone
  • chlorthalidone
  • chlorthalidon
  • chlortalidone
A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
  • Molecular weight: 338.76
  • Formula: C14H11ClN2O4S
  • CLOGP: 0.45
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 109.49
  • ALOGS: -3.81
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mg O
25 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.12 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 65 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.46 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 3.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.24 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 36 hours Lombardo F, Berellini G, Obach RS
BA (Bioavailability) 64 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.647 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 7.413 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.726 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.644 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 31.670 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 43.420 % High 1
herg hERG pIC50 4.095 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.072 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.141 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 39.180 % High 1
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,MAPKAPK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TEK 20
kinase-selectivity-class AXL,BRAF,CDK9,EIF2AK3,GRK2,MAP2K6,MAPK1,MAPKAPK3,PDK1,PDK4,PIK3CD,SIK2,STK10,STK33,TEK 15
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 2.128 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.084 High 1
mh-clint Mouse hepatocyte intrinsic clearance 2.432 High 1
mppb Mouse plasma protein binding (% unbound) 42.800 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.799 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
pppb Pig plasma protein binding (% unbound) 47.120 % High 1
rat-kpuu-brain Rat brain Kpuu 0.018 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.081 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 91.480 % High 1
rppb Rat plasma protein binding (% unbound) 37.600 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 968.278 uM High 1

Approvals:

DateAgencyCompanyOrphan
April 7, 1960 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 209.79 13.90 173 14442 133365 90480467
Hypokalaemia 102.91 13.90 116 14499 131000 90482832
Pneumonia viral 88.30 13.90 38 14577 8785 90605047
Lichen planopilaris 83.35 13.90 16 14599 184 90613648
Cardiac murmur 78.14 13.90 44 14571 18150 90595682
Presyncope 71.34 13.90 51 14564 31754 90582078
Milk-alkali syndrome 67.25 13.90 19 14596 1254 90612578
Breath sounds abnormal 65.50 13.90 37 14578 15349 90598483
Blood pressure increased 61.02 13.90 112 14503 197105 90416727
Renal impairment 54.93 13.90 76 14539 105345 90508487
Eosinophilia 44.77 13.90 37 14578 28496 90585336
Nasal congestion 40.28 13.90 58 14557 83356 90530476
Chronic obstructive pulmonary disease 39.61 13.90 54 14561 73775 90540057
Systemic infection 39.51 13.90 18 14597 4757 90609075
Synovitis 38.91 13.90 4 14611 329748 90284084
Maternal exposure during pregnancy 38.54 13.90 6 14609 360057 90253775
Stress cardiomyopathy 38.46 13.90 25 14590 13330 90600502
Myxoedema coma 35.25 13.90 9 14606 403 90613429
Pulmonary embolism 35.14 13.90 70 14545 130750 90483082
Drug interaction 34.99 13.90 111 14504 276342 90337490
Blood potassium decreased 33.66 13.90 40 14575 47687 90566145
Pericarditis 32.60 13.90 3 14612 270148 90343684
Systemic lupus erythematosus 30.80 13.90 10 14605 361886 90251946
Poor personal hygiene 30.61 13.90 8 14607 393 90613439
Treatment failure 30.47 13.90 6 14609 303922 90309910
Acute kidney injury 30.45 13.90 117 14498 320270 90293562
Diarrhoea infectious 29.25 13.90 10 14605 1239 90612593
Angle closure glaucoma 27.92 13.90 12 14603 2763 90611069
Exposure during pregnancy 27.84 13.90 3 14612 238407 90375425
Cough 26.70 13.90 124 14491 368838 90244994
Productive cough 26.67 13.90 46 14569 77017 90536815
Infusion related reaction 25.58 13.90 18 14597 416762 90197070
Hand deformity 25.55 13.90 8 14607 296354 90317478
Cockroach allergy 24.81 13.90 5 14610 75 90613757
Blood glucose increased 24.42 13.90 50 14565 95196 90518636
Irritable bowel syndrome 23.25 13.90 3 14612 207445 90406387
Catastrophic reaction 21.83 13.90 4 14611 35 90613797
Wound 21.51 13.90 11 14604 302969 90310863
Blood creatinine increased 21.17 13.90 49 14566 101337 90512495
Discomfort 20.95 13.90 9 14606 274326 90339506
Arthropathy 20.95 13.90 17 14598 366225 90247607
Joint abscess 20.51 13.90 6 14609 448 90613384
Hyperlactacidaemia 20.50 13.90 11 14604 4125 90609707
Syncope 20.30 13.90 57 14558 132606 90481226
Upper respiratory tract infection 19.50 13.90 55 14560 128263 90485569
Strabismus 19.47 13.90 9 14606 2459 90611373
Serotonin syndrome 19.25 13.90 27 14588 37860 90575972
Hepatic enzyme increased 19.11 13.90 18 14597 360718 90253114
Oedema peripheral 18.87 13.90 87 14528 257828 90356004
Renal failure 18.79 13.90 55 14560 130952 90482880
Nodal rhythm 18.75 13.90 8 14607 1810 90612022
Choroiditis 18.51 13.90 5 14610 279 90613553
Contraindicated product administered 18.13 13.90 15 14600 320124 90293708
Blister 17.02 13.90 10 14605 254988 90358844
Alopecia 16.89 13.90 34 14581 495037 90118795
Mite allergy 16.88 13.90 6 14609 834 90612998
Post procedural hypoparathyroidism 16.72 13.90 3 14612 23 90613809
Hyperkalaemia 16.52 13.90 34 14581 64930 90548902
Asthma 16.48 13.90 80 14535 242080 90371752
Nausea 16.26 13.90 260 14355 1110056 89503776
Hepatic cancer 16.21 13.90 10 14605 4871 90608961
Dehydration 16.04 13.90 68 14547 194379 90419453
Vascular access site pain 15.66 13.90 5 14610 501 90613331
Mean cell haemoglobin increased 15.57 13.90 9 14606 3896 90609936
Iron deficiency anaemia 15.32 13.90 19 14596 23643 90590189
Abdominal discomfort 15.26 13.90 34 14581 477294 90136538
Basophil count increased 15.04 13.90 6 14609 1145 90612687
Mean cell haemoglobin concentration increased 14.70 13.90 5 14610 610 90613222
Hypomagnesaemia 14.68 13.90 23 14592 35565 90578267
Delusional perception 14.56 13.90 4 14611 238 90613594
Anaemia of malignant disease 14.55 13.90 5 14610 629 90613203
Product monitoring error 14.31 13.90 9 14606 4535 90609297
Renal artery stenosis 14.30 13.90 7 14608 2170 90611662
Hypocalcaemia 14.27 13.90 25 14590 42343 90571489
Injury 14.25 13.90 7 14608 197342 90416490
Hypervitaminosis 14.22 13.90 3 14612 57 90613775
Ill-defined disorder 14.22 13.90 6 14609 184885 90428947

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 182.43 16.39 170 10293 101292 42509580
Hypokalaemia 144.11 16.39 128 10335 71593 42539279
Meningitis aseptic 101.32 16.39 39 10424 4443 42606429
Renal artery stenosis 85.62 16.39 29 10434 2288 42608584
Rectal prolapse 84.47 16.39 21 10442 547 42610325
Renal cyst haemorrhage 80.41 16.39 21 10442 669 42610203
Abdominal wall haemorrhage 71.29 16.39 18 10445 500 42610372
SARS-CoV-2 antibody test positive 70.56 16.39 17 10446 387 42610485
Vena cava injury 62.79 16.39 15 10448 329 42610543
Vascular anastomotic haemorrhage 58.96 16.39 14 10449 299 42610573
Chronic kidney disease 55.34 16.39 63 10400 47178 42563694
Carotid arteriosclerosis 55.24 16.39 21 10442 2311 42608561
Delayed graft function 52.75 16.39 21 10442 2614 42608258
Left ventricular hypertrophy 52.13 16.39 31 10432 9288 42601584
Vascular compression 50.82 16.39 13 10450 381 42610491
Aortic dilatation 50.51 16.39 18 10445 1651 42609221
Spinal osteoarthritis 48.86 16.39 29 10434 8657 42602215
Hyperparathyroidism secondary 48.78 16.39 18 10445 1824 42609048
Intraductal papillary mucinous neoplasm 47.98 16.39 13 10450 478 42610394
Perineal cyst 46.28 16.39 11 10452 236 42610636
Diverticulum intestinal 45.17 16.39 23 10440 5090 42605782
Aortic arteriosclerosis 45.14 16.39 23 10440 5097 42605775
Intervertebral disc space narrowing 44.95 16.39 15 10448 1130 42609742
Actinic keratosis 44.90 16.39 23 10440 5153 42605719
Mean cell volume increased 44.71 16.39 21 10442 3902 42606970
Hemiparaesthesia 43.27 16.39 10 10453 189 42610683
Blood 25-hydroxycholecalciferol decreased 42.69 16.39 11 10452 332 42610540
Fibrillary glomerulonephritis 41.52 16.39 8 10455 59 42610813
Hepatosplenomegaly 41.27 16.39 21 10442 4639 42606233
Choroidal effusion 39.95 16.39 10 10453 268 42610604
Spinal cord abscess 39.82 16.39 11 10452 435 42610437
Renin increased 37.52 16.39 9 10454 201 42610671
Presyncope 37.20 16.39 36 10427 22351 42588521
Spinal stenosis 35.02 16.39 21 10442 6385 42604487
Dizziness 34.89 16.39 137 10326 249117 42361755
Restless legs syndrome 34.05 16.39 24 10439 9590 42601282
Glycosylated haemoglobin increased 34.01 16.39 27 10436 12897 42597975
Hepatic steatosis 32.87 16.39 33 10430 21415 42589457
Acute kidney injury 30.22 16.39 173 10290 367164 42243708
Swelling of eyelid 29.32 16.39 13 10450 2115 42608757
Blood potassium increased 29.29 16.39 29 10434 18507 42592365
Vitamin D decreased 27.83 16.39 16 10447 4499 42606373
Squamous cell carcinoma of skin 26.06 16.39 23 10440 12703 42598169
Haemorrhoids 25.64 16.39 26 10437 17071 42593801
Febrile neutropenia 25.54 16.39 7 10456 185696 42425176
Arteriosclerosis 24.53 16.39 26 10437 17963 42592909
Bradycardia 24.09 16.39 60 10403 85424 42525448
Atrioventricular block first degree 22.51 16.39 16 10447 6475 42604397
Rhabdomyolysis 22.23 16.39 55 10408 77964 42532908
Amyloidosis 21.71 16.39 11 10452 2408 42608464
Myelitis transverse 21.07 16.39 9 10454 1338 42609534
Nocardiosis 20.84 16.39 14 10449 5176 42605696
Complications of transplanted kidney 20.45 16.39 14 10449 5336 42605536
Blood potassium decreased 20.24 16.39 25 10438 20359 42590513
Aortic valve incompetence 20.12 16.39 15 10448 6533 42604339
Oedema peripheral 19.97 16.39 76 10387 136000 42474872
Activated partial thromboplastin time prolonged 19.96 16.39 22 10441 15881 42594991
Glomerular filtration rate decreased 19.46 16.39 22 10441 16329 42594543
Renal impairment 19.09 16.39 65 10398 110163 42500709
Blood pressure fluctuation 19.07 16.39 28 10435 26880 42583992
Ventilation perfusion mismatch 18.97 16.39 5 10458 165 42610707
Gastrooesophageal reflux disease 18.79 16.39 37 10426 44986 42565886
Hyperkalaemia 18.14 16.39 52 10411 80406 42530466
Basal cell carcinoma 18.09 16.39 25 10438 22708 42588164
Benign prostatic hyperplasia 18.04 16.39 24 10439 21028 42589844
Fear 17.03 16.39 17 10446 10948 42599924
Choroidal detachment 17.01 16.39 6 10457 534 42610338
Off label use 16.45 16.39 91 10372 638244 41972628
Hyperglycaemic hyperosmolar nonketotic syndrome 16.42 16.39 8 10455 1610 42609262

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 406.07 13.21 338 21352 217315 110350294
Hypokalaemia 227.15 13.21 226 21464 182222 110385387
Presyncope 110.20 13.21 85 21605 48802 110518807
Renal artery stenosis 101.17 13.21 35 21655 3691 110563918
Renal cyst haemorrhage 83.04 13.21 21 21669 740 110566869
Lichen planopilaris 82.82 13.21 16 21674 154 110567455
SARS-CoV-2 antibody test positive 73.90 13.21 17 21673 398 110567211
Pneumonia viral 72.69 13.21 38 21652 11119 110556490
Acute kidney injury 72.66 13.21 281 21409 635149 109932460
Renal impairment 69.40 13.21 129 21561 188316 110379293
Abdominal wall haemorrhage 68.61 13.21 18 21672 735 110566874
Vena cava injury 65.79 13.21 15 21675 337 110567272
Vascular anastomotic haemorrhage 62.08 13.21 14 21676 299 110567310
Chronic kidney disease 60.94 13.21 75 21615 76216 110491393
Rectal prolapse 57.89 13.21 21 21669 2542 110565067
Left ventricular hypertrophy 56.06 13.21 34 21656 13210 110554399
Cardiac murmur 55.87 13.21 43 21647 24585 110543024
Milk-alkali syndrome 55.08 13.21 19 21671 1986 110565623
Carotid arteriosclerosis 54.29 13.21 21 21669 3036 110564573
Choroidal effusion 51.98 13.21 15 21675 875 110566734
Aortic dilatation 49.23 13.21 18 21672 2228 110565381
Perineal cyst 48.86 13.21 11 21679 233 110567376
Delayed graft function 47.57 13.21 21 21669 4236 110563373
Blood pressure increased 46.17 13.21 133 21557 258240 110309369
Vascular compression 44.89 13.21 13 21677 768 110566841
Angle closure glaucoma 44.79 13.21 19 21671 3480 110564129
Intervertebral disc space narrowing 44.57 13.21 16 21674 1880 110565729
Blood potassium decreased 44.51 13.21 54 21636 54060 110513549
Hepatic steatosis 43.91 13.21 51 21639 48780 110518829
Intraductal papillary mucinous neoplasm 43.67 13.21 13 21677 846 110566763
Aortic arteriosclerosis 43.54 13.21 27 21663 10911 110556698
Rhabdomyolysis 42.53 13.21 81 21609 120320 110447289
Hyperparathyroidism secondary 42.49 13.21 18 21672 3286 110564323
Bradycardia 42.39 13.21 94 21596 155423 110412186
Synovitis 42.16 13.21 3 21687 274089 110293520
Fibrillary glomerulonephritis 42.09 13.21 8 21682 70 110567539
Blood 25-hydroxycholecalciferol decreased 41.56 13.21 11 21679 465 110567144
Drug interaction 40.81 13.21 200 21490 499983 110067626
Actinic keratosis 40.38 13.21 22 21668 6991 110560618
Breath sounds abnormal 40.20 13.21 36 21654 25368 110542241
Mean cell volume increased 39.47 13.21 23 21667 8307 110559302
Spinal osteoarthritis 38.85 13.21 32 21658 20151 110547458
Hemiparaesthesia 38.36 13.21 10 21680 398 110567211
Spinal cord abscess 38.02 13.21 11 21679 648 110566961
Hepatosplenomegaly 37.89 13.21 21 21669 6898 110560711
Oedema peripheral 37.16 13.21 145 21545 328515 110239094
Maternal exposure during pregnancy 35.94 13.21 4 21686 254879 110312730
Blood potassium increased 35.52 13.21 38 21652 33211 110534398
Hyperkalaemia 34.69 13.21 80 21610 135716 110431893
Diverticulum intestinal 34.61 13.21 24 21666 11695 110555914
Renin increased 34.56 13.21 9 21681 357 110567252
Syncope 33.06 13.21 101 21589 202435 110365174
Febrile neutropenia 32.14 13.21 11 21679 316756 110250853
Pericarditis 32.03 13.21 3 21687 219111 110348498
Arteriosclerosis 31.33 13.21 31 21659 24736 110542873
Metabolic alkalosis 30.69 13.21 17 21673 5578 110562031
Basal cell carcinoma 30.63 13.21 41 21649 45229 110522380
Blood creatinine increased 30.60 13.21 92 21598 182797 110384812
Stress cardiomyopathy 30.30 13.21 25 21665 15781 110551828
Nasal congestion 29.75 13.21 62 21628 98220 110469389
Glycosylated haemoglobin increased 28.84 13.21 29 21661 23590 110544019
Myxoedema coma 28.76 13.21 9 21681 693 110566916
Chronic obstructive pulmonary disease 28.64 13.21 65 21625 109093 110458516
Squamous cell carcinoma of skin 28.45 13.21 25 21665 17178 110550431
Dizziness 28.00 13.21 233 21457 697960 109869649
Spinal stenosis 26.26 13.21 25 21665 19031 110548578
Treatment failure 25.84 13.21 11 21679 277223 110290386
Poor personal hygiene 25.63 13.21 8 21682 611 110566998
Vitamin D decreased 24.84 13.21 20 21670 12195 110555414
Dehydration 24.36 13.21 114 21576 279397 110288212
Systemic infection 24.16 13.21 18 21672 9801 110557808
Meningitis aseptic 24.08 13.21 18 21672 9852 110557757
Systemic lupus erythematosus 23.85 13.21 10 21680 254328 110313281
Benign prostatic hyperplasia 23.39 13.21 23 21667 18211 110549398
Hand deformity 23.20 13.21 7 21683 218499 110349110
Diarrhoea infectious 23.07 13.21 10 21680 1930 110565679
Infusion related reaction 22.43 13.21 25 21665 381137 110186472
Systolic hypertension 22.15 13.21 8 21682 956 110566653
Injury 22.14 13.21 4 21686 177261 110390348
Catastrophic reaction 21.84 13.21 4 21686 28 110567581
Hyperglycaemic hyperosmolar nonketotic syndrome 21.77 13.21 11 21679 2998 110564611
Complications of transplanted kidney 21.41 13.21 15 21675 7427 110560182
Amyloidosis 21.19 13.21 11 21679 3170 110564439
Restless legs syndrome 20.94 13.21 25 21665 24601 110543008
Swelling of eyelid 20.53 13.21 14 21676 6639 110560970
Hypotension 20.53 13.21 174 21516 523675 110043934
Eosinophilia 20.48 13.21 39 21651 57897 110509712
Iron deficiency anaemia 20.46 13.21 28 21662 31531 110536078
Sinus bradycardia 20.40 13.21 27 21663 29456 110538153
Aortic valve incompetence 20.28 13.21 17 21673 10964 110556645
Arthropathy 20.27 13.21 16 21674 287506 110280103
Irritable bowel syndrome 19.88 13.21 4 21686 164211 110403398
Liver injury 19.66 13.21 3 21687 150410 110417199
Hypocalcaemia 19.50 13.21 41 21649 65325 110502284
Activated partial thromboplastin time prolonged 19.50 13.21 23 21667 22345 110545264
Discomfort 19.25 13.21 9 21681 214698 110352911
Glomerular filtration rate decreased 19.24 13.21 26 21664 28930 110538679
Pulmonary embolism 19.07 13.21 88 21602 214386 110353223
Nocardiosis 19.04 13.21 14 21676 7472 110560137
Blood pressure inadequately controlled 18.80 13.21 14 21676 7619 110559990
Sleep disorder 18.32 13.21 8 21682 198636 110368973
Renal cyst 18.07 13.21 20 21670 18152 110549457
Myelitis transverse 18.03 13.21 9 21681 2392 110565217
Post procedural hypoparathyroidism 17.99 13.21 3 21687 11 110567598
Atrioventricular block 17.52 13.21 19 21671 16858 110550751
Atrial fibrillation 17.39 13.21 90 21600 229552 110338057
Blood glucose increased 17.07 13.21 61 21629 132435 110435174
Ill-defined disorder 16.70 13.21 5 21685 156848 110410761
Cockroach allergy 16.50 13.21 4 21686 118 110567491
Hypertensive crisis 16.37 13.21 22 21668 24350 110543259
Nausea 16.33 13.21 336 21354 1235354 109332255
Choroidal detachment 16.23 13.21 6 21684 766 110566843
Blood cholesterol increased 16.17 13.21 8 21682 184777 110382832
Ventilation perfusion mismatch 16.04 13.21 6 21684 791 110566818
Hypophagia 15.69 13.21 33 21657 52593 110515016
Hyperlactacidaemia 15.66 13.21 13 21677 8273 110559336
Blister 15.59 13.21 13 21677 227363 110340246
Haemorrhoids 15.14 13.21 26 21664 35646 110531963
Psoriatic arthropathy 15.11 13.21 10 21680 196751 110370858
Blood sodium decreased 15.05 13.21 27 21663 38292 110529317
Drug abuse 15.05 13.21 8 21682 177403 110390206
Nodal rhythm 15.03 13.21 9 21681 3414 110564195
Strabismus 14.85 13.21 9 21681 3490 110564119
Inappropriate antidiuretic hormone secretion 14.79 13.21 25 21665 33826 110533783
Myalgia 14.71 13.21 84 21606 222297 110345312
Treatment noncompliance 14.42 13.21 39 21651 72951 110494658
Drug intolerance 14.37 13.21 37 21653 406475 110161134
Rheumatoid arthritis 14.22 13.21 23 21667 299590 110268019
Intestinal angioedema 14.19 13.21 6 21684 1091 110566518
Vasoconstriction 14.12 13.21 6 21684 1104 110566505
Vascular access site pain 13.91 13.21 5 21685 590 110567019
Vertigo 13.86 13.21 43 21647 86827 110480782
Congenital aortic dilatation 13.49 13.21 3 21687 60 110567549
Therapy non-responder 13.48 13.21 7 21683 157300 110410309
Pulmonary artery dilatation 13.40 13.21 5 21685 655 110566954
Calcium ionised decreased 13.36 13.21 5 21685 661 110566948
Blood magnesium decreased 13.36 13.21 18 21672 19978 110547631
Asthenia 13.25 13.21 199 21491 688800 109878809
Angioedema 13.24 13.21 46 21644 98454 110469155
Therapy cessation 13.22 13.21 28 21662 44829 110522780
Hypervitaminosis 13.22 13.21 3 21687 66 110567543

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C03BA04 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, EXCL. THIAZIDES
Sulfonamides, plain
ATC C03BB04 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, EXCL. THIAZIDES
Sulfonamides and potassium in combination
ATC C03EA06 CARDIOVASCULAR SYSTEM
DIURETICS
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION
Low-ceiling diuretics and potassium-sparing agents
FDA PE N0000175359 Increased Diuresis
FDA EPC N0000175420 Thiazide-like Diuretic
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:145947 antiatherosclerotic agent
CHEBI has role CHEBI:231911 renoprotective agent
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004232 Diuretics
MeSH PA D045283 Natriuretic Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D049993 Sodium Chloride Symporter Inhibitors

Related Drugs by ATC class:

C03BA Sulfonamides, plain 10 drugs
clofenamideclopamideclorexolonefenquizoneindapamidemefrusidemeticranemetolazonequinethazonexipamide
C03BB Sulfonamides and potassium in combination 4 drugs
clofenamideclopamidemefrusidequinethazone
C03EA Low-ceiling diuretics and potassium-sparing agents 9 drugs
altizidebendroflumethiazidebutizidecyclopenthiazideepitizidehydrochlorothiazidemebutizidemetolazonetrichlormethiazide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Edema indication 267038008
Pulmonary Edema due to Chronic Heart Failure indication
Peripheral Edema due to Chronic Heart Failure indication
Diabetes insipidus off-label use 15771004 DOID:9409
Calcium renal calculus off-label use 427649000
Anuria contraindication 2472002 DOID:2983
Suicidal thoughts contraindication 6471006
Psoriasis contraindication 9014002 DOID:8893
Peptic ulcer contraindication 13200003 DOID:750
Hypercholesterolemia contraindication 13644009
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Electroconvulsive therapy contraindication 23835007
Complete atrioventricular block contraindication 27885002
Depressive disorder contraindication 35489007
Hyperuricemia contraindication 35885006 DOID:1920
Anaphylaxis contraindication 39579001
Hypokalemia contraindication 43339004
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Conduction disorder of the heart contraindication 44808001
Tear film insufficiency contraindication 46152009
End stage renal disease contraindication 46177005 DOID:784
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Chronic heart failure contraindication 48447003
Sinus bradycardia contraindication 49710005
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Ulcerative colitis contraindication 64766004 DOID:8577
Hypercalcemia contraindication 66931009 DOID:12678
Hypochloremic alkalosis contraindication 70134007
Oliguria contraindication 83128009
Epilepsy contraindication 84757009 DOID:1826
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Asthma contraindication 195967001 DOID:2841
Acute pancreatitis contraindication 197456007 DOID:2913
Atrioventricular block contraindication 233917008 DOID:0050820
Raynaud's phenomenon contraindication 266261006
Calculus in biliary tract contraindication 266474003
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006
Surgical procedure contraindication 387713003
Chronic myocardial ischemia contraindication 413844008 DOID:3393
First Degree Atrioventricular Heart Block contraindication
Acutely Decompensated HF Requiring Parenteral Inotropic Therapy contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.63 acidic
pKa2 9.38 acidic
pKa3 13.47 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 40MG MEDOXOMIL;12.5MG EDARBYCLOR AZURITY N202331 Dec. 20, 2011 RX TABLET ORAL 9387249 July 1, 2031 TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;25MG EDARBYCLOR AZURITY N202331 Dec. 20, 2011 RX TABLET ORAL 9387249 July 1, 2031 TREATMENT OF HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Solute carrier family 12 member 3 Transporter INHIBITOR CHEMBL CHEMBL
Carbonic anhydrase 1 Enzyme Ki 6.46 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 6.71 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.64 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 8.35 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 6.04 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 8.05 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 8.55 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 4.96 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 5.87 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 5.38 CHEMBL
Carbonic anhydrase 2 Enzyme Kd 5.56 WOMBAT-PK
N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D Enzyme ALLOSTERIC MODULATOR Kd 6.17 IUPHAR
Carbonic anhydrase 13 Enzyme Ki 7.82 CHEMBL

External reference:

IDSource
4017887 VUID
N0000146240 NUI
D00272 KEGG_DRUG
2409 RXNORM
CHEBI:3654 CHEBI
KLT PDB_CHEM_ID
CHEMBL1055 ChEMBL_ID
DB00310 DRUGBANK_ID
4364 MMSL
4432 MMSL
d00192 MMSL
002309 NDDF
387324004 SNOMEDCT_US
57893000 SNOMEDCT_US
C0008294 UMLSCUI
D002752 MESH_DESCRIPTOR_UI
2732 PUBCHEM_CID
7147 IUPHAR_LIGAND_ID
1125 INN_ID
4017887 VANDF
Q0MQD1073Q UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 0378-0213 TABLET 50 mg ORAL ANDA 24 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 0378-0222 TABLET 25 mg ORAL ANDA 24 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 0591-5782 TABLET 25 mg ORAL ANDA 17 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 0591-5783 TABLET 25 mg ORAL ANDA 17 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6900 TABLET 25 mg ORAL ANDA 21 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6900 TABLET 25 mg ORAL ANDA 21 sections
CHLORTHALIDONE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7583 TABLET 25 mg ORAL ANDA 20 sections
ATENOLOL AND CHLORTHALIDONE HUMAN PRESCRIPTION DRUG LABEL 2 10135-733 TABLET 25 mg ORAL ANDA 21 sections
ATENOLOL AND CHLORTHALIDONE HUMAN PRESCRIPTION DRUG LABEL 2 10135-734 TABLET 25 mg ORAL ANDA 21 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 16714-128 TABLET 25 mg ORAL ANDA 16 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 16714-129 TABLET 50 mg ORAL ANDA 16 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 16714-936 TABLET 25 mg ORAL ANDA 16 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 16714-937 TABLET 25 mg ORAL ANDA 16 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 21695-671 TABLET 25 mg ORAL ANDA 24 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 21695-743 TABLET 25 mg ORAL ANDA 18 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 21695-744 TABLET 25 mg ORAL ANDA 18 sections
TENORETIC HUMAN PRESCRIPTION DRUG LABEL 2 24979-256 TABLET 25 mg ORAL NDA 23 sections
TENORETIC HUMAN PRESCRIPTION DRUG LABEL 2 24979-257 TABLET 25 mg ORAL NDA 23 sections
Chlorthalidone Human Prescription Drug Label 1 27241-216 TABLET 25 mg ORAL ANDA 20 sections
Chlorthalidone Human Prescription Drug Label 1 27241-217 TABLET 50 mg ORAL ANDA 20 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 29300-333 TABLET 25 mg ORAL ANDA 19 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 29300-334 TABLET 50 mg ORAL ANDA 19 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 29300-400 TABLET 25 mg ORAL ANDA 17 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 29300-401 TABLET 25 mg ORAL ANDA 17 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 33261-942 TABLET 25 mg ORAL ANDA 18 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 43353-149 TABLET 25 mg ORAL ANDA 18 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 43353-922 TABLET 50 mg ORAL ANDA 24 sections
CHLORTHALIDONE Human Prescription Drug Label 1 43598-167 TABLET 50 mg ORAL ANDA 21 sections
CHLORTHALIDONE Human Prescription Drug Label 1 43598-170 TABLET 25 mg ORAL ANDA 21 sections
CHLORTHALIDONE Human Prescription Drug Label 1 43598-719 TABLET 25 mg ORAL ANDA 21 sections